Biotech Values

[WorstLuck]

every four weeks for the first year. In the second year, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm.

Yeah, I still don't understand the strategy here given the current alternative treatments, and potential future competiton. Kind of like betting you will do enough better than generic Eylea while both OCUL and EYPT have trouble with the indication/never get there (or any indication if off-label gets used.)

960 participants.

EYPT p2 topline Q1 next year in DME, not gonna guess how it turns out given their results in NPDr and the trial is small, so ......